Chronic Lymphocytic Leukemia

In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of treatment in patients with chronic lymphocytic leukemia.

Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.

Mazyar Shadman, MD, MPH, provides clinical insights on adverse events seen with zanubrutinib in patients with chronic lymphocytic leukemia.

A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.

The current indication of lisocabtagene maraleucel has been expanded to include adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received a prior BTK inhibitor and B-cell lymphoma 2 inhibitor.

In a matched indirect comparison of zanubrutinib vs acalabrutinib, the former showed survival and response improvements in patients with chronic lymphocytic leukemia.

In the first article of a 2-part series, Farrukh Awan, MD, discusses the current landscape of treatment for patients with chronic lymphocytic leukemia and what Burton tyrosine kinase inhibitors are having the most impact for these patients.

Lisocabtagene maraleucel given as a single administration led to rapid responses in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.

In the second article of a 2-part series, Sameer A. Parikh, MBBS, looks at the risk of cardiac related toxicities with zanubrutinib for patients with relapsed chronic lymphocytic leukemia.

In an interview, Ira Zackon, MD, emphasized the need for community-based, inclusive care, and the importance of utilizing technology to address disparities in the modern era of chronic lymphocytic leukemia treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Justin Kline, MD, discussed the importance of the ELEVATE-TN trial of acalabrutinib in treating a patient with chronic lymphocytic leukemia.

Findings from the phase 2 CAPTIVATE study demonstrate that the doublet of ibrutinib and venetoclax may be an attractive line of therapy for patients with chronic lymphocytic leukemia.

David J. Andorsky, MD, discussed real-world findings from a study which evaluated BTK inhibitors in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In the first article of a 2-part series, Sameer A. Parikh, MBBS, discusses the makeup and design of the phase 3 ALPINE study that showed the promise for the next-generation Bruton tyrosine kinase inhibitor zanubrutinib.

In an interview with Targeted Oncology, Jennifer A. Woyach, MD, discussed updated results from the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma following treatment with a covalent Bruton tyrosine kinase inhibitor.

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in leukemia and lymphoma.

Experts on leukemia review the biomarker subgroup analysis from the SEQUOIA study looking at zanubrutinib in patients with treatment-naïve CLL/SLL without 17p deletion.

Following ASH 2023, Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the ALPINE study investigating zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Jennifer A. Woyach, MD, discusses background and updated findings from the phase 1/2 BRUIN study of pirtobrutinib for the treatment of heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma after prior treatment with a covalent Bruton tyrosine kinase inhibitor.

Mazyar Shadman, MD, MPH, explains the current standard-of-care treatment for patients with chronic lymphocytic leukemia and details the factors he considers when choosing an appropriate therapy.

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

The majority of patients with relapsed chronic lymphocytic leukemia treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation.

Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.